Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Our mission is to provide innovative, cost-effective solutions to improve the quality of life of patients, with a commitment to the highest level of research and product development.

Nymox envisions creating a world in which new technologies and therapies can prevent and cure infections and provide better overall health outcomes for people around the world.

Nymox has been recognized for its contributions with multiple awards, such as the 2018 New Jersey Emerging Technology Awards and the 2019 NJBIZ Healthcare Heroes Award for Excellence in Life Sciences.